Trials / Completed
CompletedNCT01990469
Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 219 (actual)
- Sponsor
- LG Life Sciences · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
After a screening, a 2-week, single-blind placebo run-in, 174 patients will be randomized in a 1 : 1 ratio to the addition of either once-daily Gemigliptin 50 mg or placebo to ongoing stable doses of glimepiride in combination with metformin for 24 weeks.
Detailed description
Subjects will visit the center on Week 6, 12, 18 and 24 during the entire 24-week treatment period. Total study duration will be approximately 26weeks and the subjects will be to practice exercise/diet control together.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemigliptin | DPP-4 inhibitor |
| DRUG | Gemigliptin placebo | Placebo of Gemigliptin |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2013-11-21
- Last updated
- 2016-04-19
Source: ClinicalTrials.gov record NCT01990469. Inclusion in this directory is not an endorsement.